$SNWV
SANUWAVE Health, Inc.

2020 Q4 Form 10-Q Financial Statement

#000114036120026351 Filed on November 23, 2020

View on sec.gov

Income Statement

Concept 2020 Q4 2020 Q3 2019 Q3
Revenue $1.860M $1.967M $197.6K
YoY Change 453.32% 895.19% -66.83%
Cost Of Revenue $500.0K $548.4K $122.9K
YoY Change 266.92% 346.14% -33.04%
Gross Profit $1.360M $1.418M $74.72K
YoY Change 580.41% 1798.48% -81.87%
Gross Profit Margin 73.12% 72.12% 37.8%
Selling, General & Admin $6.940M $6.428M $2.138M
YoY Change 191.17% 200.64% -11.47%
% of Gross Profit 510.29% 453.16% 2861.64%
Research & Development $260.0K $432.2K $299.9K
YoY Change -17.22% 44.1% -54.68%
% of Gross Profit 19.12% 30.47% 401.39%
Depreciation & Amortization $565.1K $327.1K $22.34K
YoY Change 1719.35% 1364.28% 231.95%
% of Gross Profit 41.55% 23.06% 29.9%
Operating Expenses $7.530M $7.187M $2.460M
YoY Change 175.96% 192.12% -20.18%
Operating Profit -$6.170M -$6.369M -$2.386M
YoY Change 143.99% 166.97% -10.66%
Interest Expense $1.160M -$6.366M -$362.4K
YoY Change -624.1% 1656.82% -119.64%
% of Operating Profit
Other Income/Expense, Net -$2.920M -$6.269M -$362.4K
YoY Change 1630.03%
Pretax Income $11.66M -$12.64M -$2.748M
YoY Change -523.99% 359.89% 233.04%
Income Tax $0.00
% Of Pretax Income
Net Earnings $11.66M -$12.64M -$2.748M
YoY Change -523.99% 359.9% 233.04%
Net Earnings / Revenue 626.88% -642.54% -1390.42%
Basic Earnings Per Share -$0.03
Diluted Earnings Per Share $21.86K -$0.03 -$13.00K
COMMON SHARES
Basic Shares Outstanding 467.2M 384.5M
Diluted Shares Outstanding 384.5M

Balance Sheet

Concept 2020 Q4 2020 Q3 2019 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $2.440M $5.392M $402.7K
YoY Change 38.6% 1238.99% 456.85%
Cash & Equivalents $2.437M $5.392M $402.7K
Short-Term Investments
Other Short-Term Assets $180.0K $627.8K $208.1K
YoY Change 43.53% 201.63% 23.53%
Inventory $2.956M $2.956M $290.9K
Prepaid Expenses
Receivables $2.356M $1.396M $56.31K
Other Receivables $0.00 $0.00 $0.00
Total Short-Term Assets $7.928M $9.955M $958.0K
YoY Change 216.57% 939.08% 51.0%
LONG-TERM ASSETS
Property, Plant & Equipment $471.0K $979.7K $656.2K
YoY Change 401.31% 49.29% 803.4%
Goodwill $7.260M $7.260M
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $28.00K $31.01K $30.06K
YoY Change -33.22% 3.16% 82.18%
Total Long-Term Assets $15.10M $22.91M $686.3K
YoY Change 1620.42% 3238.5% 669.98%
TOTAL ASSETS
Total Short-Term Assets $7.928M $9.955M $958.0K
Total Long-Term Assets $15.10M $22.91M $686.3K
Total Assets $23.03M $32.87M $1.644M
YoY Change 580.87% 1898.79% 127.24%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $4.454M $2.322M $1.697M
YoY Change 209.43% 36.84% 8.72%
Accrued Expenses $2.127M $1.604M $3.907M
YoY Change 122.23% -58.95% 84.65%
Deferred Revenue $32.00K $65.04K
YoY Change -51.94%
Short-Term Debt $0.00 $0.00 $7.785M
YoY Change -100.0% -100.0% -9.43%
Long-Term Debt Due $16.59M $4.187M
YoY Change 13542.19%
Total Short-Term Liabilities $36.17M $19.72M $14.54M
YoY Change 191.37% 35.55% 2.68%
LONG-TERM LIABILITIES
Long-Term Debt $143.0K $10.88M $0.00
YoY Change -47.28%
Other Long-Term Liabilities $200.0K $268.3K $417.7K
YoY Change -73.65% -35.76% 1509.05%
Total Long-Term Liabilities $571.0K $14.02M $417.7K
YoY Change -44.58% 3257.24% 1509.05%
TOTAL LIABILITIES
Total Short-Term Liabilities $36.17M $19.72M $14.54M
Total Long-Term Liabilities $571.0K $14.02M $417.7K
Total Liabilities $36.75M $33.74M $14.96M
YoY Change 173.29% 125.49% 5.43%
SHAREHOLDERS EQUITY
Retained Earnings -$156.7M -$138.4M
YoY Change 24.6%
Common Stock $471.0K $466.1K
YoY Change 60.32%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity -$13.72M -$9.099M -$13.32M
YoY Change
Total Liabilities & Shareholders Equity $23.03M $32.87M $1.644M
YoY Change 580.87% 1898.79% 127.24%

Cashflow Statement

Concept 2020 Q4 2020 Q3 2019 Q3
OPERATING ACTIVITIES
Net Income $11.66M -$12.64M -$2.748M
YoY Change -523.99% 359.9% 233.04%
Depreciation, Depletion And Amortization $565.1K $327.1K $22.34K
YoY Change 1719.35% 1364.28% 231.95%
Cash From Operating Activities $22.50M -$5.268M -$1.298M
YoY Change -1403.47% 305.86% 93.28%
INVESTING ACTIVITIES
Capital Expenditures $89.14K -$34.28K -$3.150K
YoY Change -457.27% 988.25% -85.79%
Acquisitions
YoY Change
Other Investing Activities $40.00M -$18.89M
YoY Change
Cash From Investing Activities $40.09M -$18.92M -$3.150K
YoY Change -160777.92% 600670.79% -85.79%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 870.0 29.15M 1.535M
YoY Change -99.97% 1798.69% 1389.7%
NET CHANGE
Cash From Operating Activities 22.50M -5.268M -1.298M
Cash From Investing Activities 40.09M -18.92M -3.150K
Cash From Financing Activities 870.0 29.15M 1.535M
Net Change In Cash 62.59M 4.958M 234.1K
YoY Change 4467.57% 2017.46% -139.64%
FREE CASH FLOW
Cash From Operating Activities $22.50M -$5.268M -$1.298M
Capital Expenditures $89.14K -$34.28K -$3.150K
Free Cash Flow $22.41M -$5.234M -$1.295M
YoY Change -1417.35% 304.2% 99.39%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1439413
CY2020Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
2322192
CY2019Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
75543
CY2020Q3 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
1395815
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1111109
CY2020Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1603543
CY2020Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
370985
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
134970
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-62234
CY2020Q3 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-61365
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
115457808
CY2020Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
137120956
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
21900
CY2019Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
224400
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
31758
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
560682
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
0
us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
560682
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
36067
CY2019Q4 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
72376
CY2020Q3 us-gaap Allowance For Doubtful Accounts Receivable Current
AllowanceForDoubtfulAccountsReceivableCurrent
32558
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
0
us-gaap Amortization Of Financing Costs
AmortizationOfFinancingCosts
214431
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
70358861
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
252403169
CY2019Q4 us-gaap Assets
Assets
3381992
CY2020Q3 us-gaap Assets
Assets
32866106
CY2019Q4 us-gaap Assets Current
AssetsCurrent
2504358
CY2020Q3 us-gaap Assets Current
AssetsCurrent
9954632
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
5973538
CY2019Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2325640
CY2020Q3 us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
2770646
us-gaap Business Acquisitions Pro Forma Revenue
BusinessAcquisitionsProFormaRevenue
6810404
CY2020Q3 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
63868
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
71918
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-16739356
CY2020Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-5419040
CY2019Q3 us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-4863590
us-gaap Business Acquisitions Pro Forma Net Income Loss
BusinessAcquisitionsProFormaNetIncomeLoss
-14855293
CY2020Q3 us-gaap Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount
BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount
0
CY2020Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5391591
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
1760455
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
3631136
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
38107
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1760455
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
364549
CY2020Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5391591
CY2019Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
402656
CY2019Q4 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
9474091
CY2020Q3 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
157106736
CY2020Q3 us-gaap Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights
ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
54119742
CY2020Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
293780400
CY2020Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
466094621
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
355000000
CY2020Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
600000000
CY2020Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
466094621
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
293780400
CY2020Q3 us-gaap Common Stock Value
CommonStockValue
466095
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
293781
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-12645029
CY2020Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-6008938
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7666614
CY2019Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-2762079
CY2019Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
22338
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
2860769
us-gaap Debt Conversion Converted Instrument Amount1
DebtConversionConvertedInstrumentAmount1
564729
CY2020Q3 us-gaap Debt Conversion Converted Instrument Warrants Or Options Issued1
DebtConversionConvertedInstrumentWarrantsOrOptionsIssued1
8275235
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
444908
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
40150
CY2019Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
639801
CY2020Q3 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
110556
CY2019Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
66577
CY2020Q3 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
65037
CY2020Q3 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
45519
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
573224
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
1918254
CY2020Q3 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
4000000
CY2019Q4 us-gaap Convertible Notes Payable Current
ConvertibleNotesPayableCurrent
0
us-gaap Cost Of Revenue
CostOfRevenue
402657
CY2020Q3 us-gaap Cost Of Revenue
CostOfRevenue
548406
CY2019Q3 us-gaap Cost Of Revenue
CostOfRevenue
122923
us-gaap Cost Of Revenue
CostOfRevenue
663630
CY2019Q4 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
2951845
CY2020Q3 us-gaap Debt Instrument Unamortized Discount Premium And Debt Issuance Costs Net
DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
1600115
CY2020Q3 us-gaap Depreciation And Amortization
DepreciationAndAmortization
327120
us-gaap Depreciation And Amortization
DepreciationAndAmortization
40150
us-gaap Depreciation And Amortization
DepreciationAndAmortization
444908
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-13199
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
CY2019Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
0
us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-503234
CY2020Q3 us-gaap Gains Losses On Extinguishment Of Debt
GainsLossesOnExtinguishmentOfDebt
-503234
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
0
CY2019Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1802659
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9529218
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4746519
CY2020Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
5054508
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
8028
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
114806
CY2020Q3 us-gaap Finance Lease Weighted Average Discount Rate Percent
FinanceLeaseWeightedAverageDiscountRatePercent
0.126
us-gaap Financing Receivable Accrued Interest Writeoff
FinancingReceivableAccruedInterestWriteoff
191031
us-gaap Financing Receivable Accrued Interest Writeoff
FinancingReceivableAccruedInterestWriteoff
1139904
us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-32103
CY2019Q4 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
121634
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Two
FinanceLeaseLiabilityPaymentsDueYearTwo
199793
CY2020Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
58648
CY2020Q3 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
284588
CY2019Q4 us-gaap Finance Lease Liability Noncurrent
FinanceLeaseLiabilityNoncurrent
271240
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2020Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.02
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.04
CY2019Q3 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.01
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
13152
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1036
CY2020Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2544768
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1452910
CY2019Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
0
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1036101
us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-227669
CY2020Q3 us-gaap Fair Value Adjustment Of Warrants
FairValueAdjustmentOfWarrants
-1036101
CY2020Q2 us-gaap Finance Lease Liability Payments Due Year Three
FinanceLeaseLiabilityPaymentsDueYearThree
18388
CY2020Q3 us-gaap Finance Lease Right Of Use Asset
FinanceLeaseRightOfUseAsset
462405
CY2020Q3 us-gaap Finance Lease Liability
FinanceLeaseLiability
472004
CY2020Q3 us-gaap Finance Lease Liability Current
FinanceLeaseLiabilityCurrent
187416
CY2020Q3 us-gaap Finance Lease Weighted Average Remaining Lease Term1
FinanceLeaseWeightedAverageRemainingLeaseTerm1
P2Y8M12D
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
234593
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
511422
CY2019Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-4840
CY2020Q3 us-gaap Foreign Currency Transaction Gain Loss Before Tax
ForeignCurrencyTransactionGainLossBeforeTax
-23836
CY2020Q3 us-gaap Goodwill
Goodwill
7259795
CY2019Q4 us-gaap Goodwill
Goodwill
0
CY2019Q3 us-gaap Gross Profit
GrossProfit
74717
us-gaap Gross Profit
GrossProfit
1535158
CY2020Q3 us-gaap Gross Profit
GrossProfit
1418490
us-gaap Gross Profit
GrossProfit
289922
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-529245
us-gaap Increase Decrease In Derivative Liabilities
IncreaseDecreaseInDerivativeLiabilities
-48425
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
882779
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
118908
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-197301
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
1280454
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
127586
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
492434
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
0
us-gaap Increase Decrease In Due From Related Parties
IncreaseDecreaseInDueFromRelatedParties
-1228
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
863400
us-gaap Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
1091858
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
13567
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
-10921
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
136555
us-gaap Increase Decrease In Inventories
IncreaseDecreaseInInventories
-66884
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
83007
us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
502346
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
508193
us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
431070
CY2020Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
61334
CY2019Q3 us-gaap Interest Expense Related Party
InterestExpenseRelatedParty
175522
CY2019Q4 us-gaap Interest Payable Current
InterestPayableCurrent
0
CY2020Q3 us-gaap Interest Payable Current
InterestPayableCurrent
354062
us-gaap Interest Expense Debt
InterestExpenseDebt
878331
us-gaap Interest Expense Debt
InterestExpenseDebt
1120440
CY2020Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
690659
CY2019Q3 us-gaap Interest Expense Debt
InterestExpenseDebt
182001
CY2019Q4 us-gaap Inventory Finished Goods
InventoryFinishedGoods
357264
CY2020Q3 us-gaap Inventory Finished Goods
InventoryFinishedGoods
2273436
CY2020Q3 us-gaap Inventory Raw Materials
InventoryRawMaterials
266039
CY2019Q4 us-gaap Inventory Raw Materials
InventoryRawMaterials
185691
CY2020Q3 us-gaap Inventory Net
InventoryNet
2539475
CY2019Q4 us-gaap Inventory Net
InventoryNet
542955
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
0
us-gaap Issuance Of Stock And Warrants For Services Or Claims
IssuanceOfStockAndWarrantsForServicesOrClaims
1797500
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
68017
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
538055
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
3345
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
96195
CY2020Q3 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
290552
CY2020Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
32866106
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
3381992
CY2020Q3 us-gaap Liabilities
Liabilities
33739108
CY2019Q4 us-gaap Liabilities
Liabilities
13445593
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1030241
CY2020Q3 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
14023530
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
12415352
CY2020Q3 us-gaap Liabilities Current
LiabilitiesCurrent
19715578
us-gaap Nature Of Operations
NatureOfOperations
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><table cellpadding="0" cellspacing="0" class="DSPFListTable" style="width: 100%; font-family: 'Times New Roman'; font-size: 10pt;"><tr style="vertical-align: top;"><td style="vertical-align: top; width: 36pt;"><div style="text-align: justify;"><font style="font-weight: bold;">1.</font></div></td><td style="align: left; vertical-align: top; width: auto;"><div style="text-align: justify;"><font style="font-weight: bold;">Nature of the Business</font></div></td></tr></table><div><br /></div><div style="text-align: justify; text-indent: 36pt;">SANUWAVE Health, Inc. and Subsidiaries (the &#8220;Company&#8221;) is focused on the research, development, and commercialization of its patented noninvasive and biological response activating medical systems for the repair and regeneration of skin, musculoskeletal tissue, and vascular structures. Through its recent acquisition of Celularity&#8217;s UltraMIST&#174; assets, SANUWAVE now combines two highly complementary and market-cleared energy transfer technologies and two human tissue biologic products, which creates a platform of scale with an end-to-end product offering in the advanced wound care market.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;"><font style="color: #000000;">The Company&#8217;s lead regenerative product in the United States is the dermaPACE</font><font style="color: rgb(0, 0, 0);">&#174;</font>&#160;<font style="color: rgb(0, 0, 0);">device, used for treating diabetic foot ulcers, which was subject to two double-blinded, randomized Phase III clinical studies.</font> On December 28, 2017, the U.S. Food and Drug Administration (FDA) granted the Company&#8217;s request to classify the dermaPACE System as a Class II device via the <font style="font-style: italic;">de novo</font> process. As a result of this decision, the Company was able to immediately market the product for the treatment of Diabetic Foot Ulcers (DFU) as described in the De Novo request, subject to the general control provisions of the FD&amp;C Act and the special controls identified in this order.</div><div><br /></div><div style="text-indent: 36pt;">On August 6, 2020 the Company entered into an Asset Purchase Agreement with Celularity Inc. (&#8220;Celularity&#8221;) pursuant to which the Company acquired Celularity&#8217;s UltraMIST assets, as more fully described in Note 4. The UltraMIST&#174; System is a proprietary technology cleared by the FDA for the promotion of wound healing through wound cleansing and maintenance debridement combined with ultrasound energy deposited inside the wound that stimulated tissue regeneration.</div><div><br /></div><div style="text-indent: 36pt;">In connection with the Asset Purchase Agreement, on August 6, 2020, the Company entered into a license and marketing agreement with Celularity pursuant to which Celularity granted to the Company a license to the Celularity wound care biologic products, Biovance&#174; and Interfyl&#174; (the &#8220;License Agreement&#8221;). The License Agreement provides the Company with an exclusive license to use, market, distribute and sell Biovance&#174; in the &#8220;Field&#8221; and &#8220;Territory&#8221; (each as defined in the License Agreement), and a non-exclusive license to use, market, distribute and sell Interfyl&#174; in the Field in the Territory. The License Agreement has an initial five year term, after which it automatically renews for additional one year periods, unless either party gives written notice at least 180 days prior to the expiration of the current term.</div><div><br /></div><div style="text-align: justify; text-indent: 36pt;"><font style="color: #000000;">The Company&#8217;s portfolio of regenerative medicine products and product candidates activate tissue regeneration biological signaling and angiogenic responses, producing new vascularization and microcirculatory improvement combined with tissue growth which helps restore the body&#8217;s normal healing processes. The Company applies and researches its patented energy transfer technologies in wound healing, orthopedic/spine, plastic/cosmetic and cardiac/endovascular conditions. The Company is marketing its dermaPACE System for treatment usage in the United States and is able to</font> generate revenue from sales of the European Conformity Marking (CE Mark) devices and accessories in Europe, Canada, Asia, and Asia/Pacific. The Company generates revenue streams from dermaPACE treatments, product sales, licensing transactions and other activities.</div><div><br /></div><div style="text-indent: 36pt;">In March 2020, the World Health Organization characterized COVID-19 as a pandemic and the President of the United States declared the COVID-19 outbreak a national emergency. Since then, the COVID-19 pandemic has rapidly spread across the globe and has already resulted in significant volatility, uncertainty and economic disruption. The primary impact of the COVID-19 pandemic has been seen in our dermaPACE System placements in the United States as our treatment is not widely recognized as an &#8220;essential&#8221; service. In addition, stay-at-home policies deployed to combat the spread of COVID-19 has greatly constrained visits to wound care centers, doctor&#8217;s offices and hospitals since late March 2020 and continuing as of this filing and have therefore delayed placements of new devices that were included in our revenue forecast. The future impacts of the pandemic and any resulting economic impact are largely unknown and rapidly evolving. It is difficult at this time to predict the impact that COVID-19 will have on the Company&#8217;s business, financial position and operating results in future periods due to numerous uncertainties. The Company is closely monitoring the impact of the pandemic on all aspects of its business and operations including its recent acquired assets.</div><div><u></u></div><div><br /></div><div style="text-align: justify; text-indent: 36pt; font-style: italic; font-weight: bold;"><u>Basis of Presentation</u></div><div><br /></div><div style="text-indent: 36pt;"><font style="color: rgb(0, 0, 0);">The accompanying unaudited condensed consolidated financial statements of the Company have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q and Article 8-03 of Regulation S-X. Accordingly, these condensed consolidated financial statements do not include all the information and footnotes required by U.S. Generally Accepted Accounting Principles (&#8220;GAAP&#8221;) for complete financial statements. The financial information as of</font> September 30, 2020 <font style="color: rgb(0, 0, 0);">and for the three and nine months ended</font> September 30, 2020 <font style="color: rgb(0, 0, 0);">and 2019 is unaudited; however, in the opinion of management, all adjustments (consisting of normal recurring accruals) considered necessary for a fair presentation have been included. Operating results for the three and nine months ended September 30, 2020 are not necessarily indicative of the results that may be expected for any other interim period or for the year ending December 31, 2020.</font></div><div><br /></div><div style="text-align: justify; color: rgb(0, 0, 0);">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; &#160;The condensed consolidated balance sheet at December 31, 2019 has been derived from the audited consolidated financial statements at that date but does not include all of the information and footnotes required by U.S. GAAP for complete financial statements. These financial statements should be read in conjunction with the Company&#8217;s Form 10-K filed with the Securities and Exchange Commission on March 30, 2020 (the &#8220;2019 Annual Report&#8221;). </div></div>
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9779889
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-4684611
us-gaap Net Income Loss
NetIncomeLoss
-12645898
us-gaap Net Income Loss
NetIncomeLoss
-7679766
CY2019Q3 us-gaap Net Income Loss
NetIncomeLoss
-2748018
CY2020Q3 us-gaap Net Income Loss
NetIncomeLoss
-6011730
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-28990
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-20039142
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
33449131
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4738556
us-gaap Noncash Or Part Noncash Acquisition Debt Assumed1
NoncashOrPartNoncashAcquisitionDebtAssumed1
0
us-gaap Noncash Or Part Noncash Acquisition Debt Assumed1
NoncashOrPartNoncashAcquisitionDebtAssumed1
4000000
CY2020Q3 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
321821
CY2019Q4 us-gaap Notes Payable To Bank Current
NotesPayableToBankCurrent
0
CY2019Q4 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
0
CY2020Q3 us-gaap Notes Payable To Bank Noncurrent
NotesPayableToBankNoncurrent
142514
CY2020Q3 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
0
CY2020Q3 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
14198799
CY2020Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
31010
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
41931
CY2020Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
2958
CY2019Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
1489
CY2020Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
4826
CY2019Q4 us-gaap Notes Payable Related Parties Classified Current
NotesPayableRelatedPartiesClassifiedCurrent
5372743
CY2020Q3 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.12
CY2020Q3 us-gaap Operating Lease Liability
OperatingLeaseLiability
474187
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
185777
CY2020Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
222815
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
173270
CY2020Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
251372
CY2020Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
84115
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
148172
CY2019Q3 us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
49217
us-gaap Operating Leases Rent Expense Net
OperatingLeasesRentExpenseNet
201991
us-gaap Operating Expenses
OperatingExpenses
6555525
us-gaap Operating Expenses
OperatingExpenses
13372419
CY2020Q3 us-gaap Operating Expenses
OperatingExpenses
7187258
CY2019Q3 us-gaap Operating Expenses
OperatingExpenses
2460372
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
323661
CY2020Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
442197
CY2020Q3 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2020Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-5768768
CY2019Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-2385655
us-gaap Operating Income Loss
OperatingIncomeLoss
-11837261
us-gaap Operating Income Loss
OperatingIncomeLoss
-6265603
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
869
CY2019Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-14061
CY2020Q3 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
2792
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
13152
CY2019Q4 us-gaap Other Intangible Assets Net
OtherIntangibleAssetsNet
0
CY2020Q2 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-6749
CY2019Q1 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
-2398
CY2019Q3 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Gain Loss Arising During Period Net Of Tax
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationGainLossArisingDuringPeriodNetOfTax
14061
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-1414163
CY2019Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-362363
CY2020Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-242962
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-808637
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
13406
CY2020Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5586
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
20000000
us-gaap Payments To Acquire Businesses And Interest In Affiliates
PaymentsToAcquireBusinessesAndInterestInAffiliates
0
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28990
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
39142
CY2020Q3 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2020Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2020Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
125405
CY2020Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
627751
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1378142
us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
10000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
1100000
us-gaap Proceeds From Convertible Debt
ProceedsFromConvertibleDebt
0
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
2450000
us-gaap Proceeds From Issuance Of Convertible Preferred Stock
ProceedsFromIssuanceOfConvertiblePreferredStock
0
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
0
us-gaap Proceeds From Issuance Of Senior Long Term Debt
ProceedsFromIssuanceOfSeniorLongTermDebt
13346547
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
0
us-gaap Proceeds From Related Party Debt
ProceedsFromRelatedPartyDebt
2055414
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
0
us-gaap Proceeds From Short Term Debt
ProceedsFromShortTermDebt
1215000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
44250
CY2019Q2 us-gaap Profit Loss
ProfitLoss
-2734431
CY2020Q3 us-gaap Profit Loss
ProfitLoss
-6011730
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-2197317
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-3001148
CY2020Q2 us-gaap Profit Loss
ProfitLoss
-3633020
CY2019Q3 us-gaap Profit Loss
ProfitLoss
-2748018
us-gaap Profit Loss
ProfitLoss
-7679766
us-gaap Profit Loss
ProfitLoss
-12645898
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
512042
CY2020Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
979673
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-18835
us-gaap Provision For Doubtful Accounts
ProvisionForDoubtfulAccounts
-39818
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
0
us-gaap Right Of Use Asset Obtained In Exchange For Finance Lease Liability
RightOfUseAssetObtainedInExchangeForFinanceLeaseLiability
127611
us-gaap Related Party Transaction Rate
RelatedPartyTransactionRate
0.08
us-gaap Related Party Transaction Date
RelatedPartyTransactionDate
2018-12-31
CY2019Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
197640
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
692579
CY2020Q3 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
1966896
us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
2198788
CY2019Q3 us-gaap Revenues
Revenues
197640
us-gaap Revenues
Revenues
2198788
CY2020Q3 us-gaap Revenues
Revenues
1966896
us-gaap Revenues
Revenues
692579
us-gaap Repayments Of Debt
RepaymentsOfDebt
0
us-gaap Repayments Of Debt
RepaymentsOfDebt
5457663
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
983816
CY2019Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
299903
CY2020Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
432155
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
867825
CY2020Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-138398688
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-125752956
CY2019 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y7M6D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P6Y1M20D
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y3M18D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P1Y3M18D
CY2020Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
1994741
CY2019Q4 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
2085866
CY2019Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
335472
CY2020Q3 us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
1373475
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
2414477
us-gaap Selling And Marketing Expense
SellingAndMarketingExpense
901031
CY2019Q4 us-gaap Senior Long Term Notes
SeniorLongTermNotes
0
CY2020Q3 us-gaap Senior Long Term Notes
SeniorLongTermNotes
10448039
us-gaap Share Based Compensation
ShareBasedCompensation
256158
us-gaap Share Based Compensation
ShareBasedCompensation
21900
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.9276
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
0.9276
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
1500000
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0015
CY2020Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
60000
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.04
CY2019 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
0.04
CY2019 us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
2.00
us-gaap Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit
ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
2.00
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
587233
CY2020Q3 us-gaap Short Term Borrowings
ShortTermBorrowings
0
CY2020Q2 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
517500
CY2020Q1 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
200000
CY2020Q3 us-gaap Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
1080000
CY2020Q1 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
2098
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
0
us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
18098
CY2019Q1 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
266667
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
225000
CY2020Q2 us-gaap Stock Issued During Period Value Other
StockIssuedDuringPeriodValueOther
16000
CY2019Q3 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
581818
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
180000
CY2020Q3 us-gaap Stockholders Equity
StockholdersEquity
-873002
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
-10063601
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-15356099
CY2019Q3 us-gaap Stockholders Equity
StockholdersEquity
-13318174
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-16355506
CY2020Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
44250
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
457501
CY2019Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
3973037
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-15693947
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
-14822533
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
-12561941
us-gaap Use Of Estimates
UseOfEstimates
<div style="font-family: 'Times New Roman'; font-size: 10pt;"><div style="text-align: justify; text-indent: 36pt;"><font style="font-weight: bold; font-style: italic;">Estimates</font> &#8211; These condensed consolidated financial statements have been prepared in accordance with U.S. GAAP. Because a precise determination of assets and liabilities, and correspondingly revenues and expenses, depend on future events, the preparation of condensed consolidated financial statements for any period necessarily involves the use of estimates and assumptions. Actual amounts may differ from these estimates. These condensed consolidated financial statements have, in management&#8217;s opinion, been properly prepared within reasonable limits of materiality and within the framework of the accounting policies summarized herein. Significant estimates include the recording of allowances for doubtful accounts, estimate of the net realizable value of inventory, the determination of the valuation allowances for deferred taxes the estimated fair value of stock-based compensation, debt discounts and warrants, and valuation of acquired assets related to the acquisition of UltraMIST (Note 4).</div></div>
CY2020Q3 us-gaap Warrants And Rights Outstanding
WarrantsAndRightsOutstanding
7306165
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
323730859
CY2020Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
302119428
CY2019Q3 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
211423362
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
181088995
dei Amendment Flag
AmendmentFlag
false
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Period End Date
DocumentPeriodEndDate
2020-09-30
dei Entity Address State Or Province
EntityAddressStateOrProvince
NV
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Registrant Name
EntityRegistrantName
SANUWAVE Health, Inc.
dei Entity Central Index Key
EntityCentralIndexKey
0001417663
CY2019Q4 snwv Accrued Interest Payable Related Parties Current
AccruedInterestPayableRelatedPartiesCurrent
1859977
CY2019Q4 snwv Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
0
CY2020Q3 snwv Convertible Notes Payable Related Parties Current
ConvertibleNotesPayableRelatedPartiesCurrent
1596254
CY2019Q4 snwv Warrant Liability
WarrantLiability
0
CY2020Q3 snwv Warrant Liability
WarrantLiability
2880055
CY2019Q1 snwv Reclassification Of Warrant Liability To Equity Due To Adoption Of Accounting Standard
ReclassificationOfWarrantLiabilityToEquityDueToAdoptionOfAccountingStandard
1542000
CY2019Q2 snwv Stock Issued During Period Value Cashless Warrant Exercises
StockIssuedDuringPeriodValueCashlessWarrantExercises
16000
CY2020Q4 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
467194621
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q3
dei Document Type
DocumentType
10-Q
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Shell Company
EntityShellCompany
false
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Small Business
EntitySmallBusiness
true
CY2020Q3 snwv Line Of Credit Related Parties Current
LineOfCreditRelatedPartiesCurrent
0
CY2019Q4 snwv Line Of Credit Related Parties Current
LineOfCreditRelatedPartiesCurrent
212388
CY2019Q4 snwv Advances From Related Parties Current
AdvancesFromRelatedPartiesCurrent
18098
CY2020Q3 snwv Advances From Related Parties Current
AdvancesFromRelatedPartiesCurrent
0
CY2020Q3 snwv Accrued Interest Payable Related Parties Current
AccruedInterestPayableRelatedPartiesCurrent
28864
CY2019Q1 snwv Stock Issued During Period Value Cashless Warrant Exercises
StockIssuedDuringPeriodValueCashlessWarrantExercises
0
CY2019Q3 snwv Stock Issued During Period Value Cashless Warrant Exercises
StockIssuedDuringPeriodValueCashlessWarrantExercises
20000
CY2020Q2 snwv Stock Issued During Period Value Private Investment In Public Equity Pipe
StockIssuedDuringPeriodValuePrivateInvestmentInPublicEquityPIPE
150000
CY2019Q2 snwv Stock Issued During Period Warrants Exercised Value
StockIssuedDuringPeriodWarrantsExercisedValue
1350057
CY2020Q1 snwv Stock Issued During Period Warrants Exercised Value
StockIssuedDuringPeriodWarrantsExercisedValue
10000
CY2019Q3 snwv Stock Issued During Period Warrants Exercised Value
StockIssuedDuringPeriodWarrantsExercisedValue
972034
CY2019Q1 snwv Stock Issued During Period Warrants Exercised Value
StockIssuedDuringPeriodWarrantsExercisedValue
53200
snwv Stock Issued During Period Shares Conversion Of Short Term Notes
StockIssuedDuringPeriodSharesConversionOfShortTermNotes
2250000
CY2020Q2 snwv Stock Issued During Period Value Conversion Of Short Term Notes
StockIssuedDuringPeriodValueConversionOfShortTermNotes
90745
CY2020Q3 snwv Stock Issued During Period Value Conversion Of Short Term Notes
StockIssuedDuringPeriodValueConversionOfShortTermNotes
210000
CY2020Q1 snwv Stock Issued During Period Value Conversion Of Short Term Notes
StockIssuedDuringPeriodValueConversionOfShortTermNotes
263984
snwv Stock Issued During Period Shares Conversion Of Note Payable Related Party Debt
StockIssuedDuringPeriodSharesConversionOfNotePayableRelatedPartyDebt
15475235
CY2020Q3 snwv Stock Issued During Period Value Conversion Of Note Payable Related Party Debt
StockIssuedDuringPeriodValueConversionOfNotePayableRelatedPartyDebt
2291047
snwv Stock Issued During Period Value Conversion Of Note Payable Related Party Debt
StockIssuedDuringPeriodValueConversionOfNotePayableRelatedPartyDebt
2291047
CY2020Q3 snwv Stock Issued During Period Value Private Investment In Public Equity Pipe Stock And Warrants
StockIssuedDuringPeriodValuePrivateInvestmentInPublicEquityPIPEStockAndWarrants
13882516
CY2020Q3 snwv Stock Issued During Period Value Inducement Shares
StockIssuedDuringPeriodValueInducementShares
44740
snwv Warrants Issued For Consulting Services
WarrantsIssuedForConsultingServices
36067
snwv Warrants Issued For Consulting Services
WarrantsIssuedForConsultingServices
0
snwv Conversion Of Line Of Credit Related Parties To Equity
ConversionOfLineOfCreditRelatedPartiesToEquity
0
snwv Conversion Of Line Of Credit Related Parties To Equity
ConversionOfLineOfCreditRelatedPartiesToEquity
680000
snwv Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
1542000
snwv Reclassification Of Warrant Liability To Equity
ReclassificationOfWarrantLiabilityToEquity
0
snwv Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
9513
snwv Increase Decrease In Operating Leases
IncreaseDecreaseInOperatingLeases
0
snwv Waived Proceeds From Warrant Exercise
WaivedProceedsFromWarrantExercise
-36000
snwv Waived Proceeds From Warrant Exercise
WaivedProceedsFromWarrantExercise
0
snwv Interest Payable Related Parties
InterestPayableRelatedParties
508193
snwv Interest Payable Related Parties
InterestPayableRelatedParties
696208
CY2019Q4 snwv Accrued Clinical Study Expenses Current
AccruedClinicalStudyExpensesCurrent
13650
snwv Proceeds From Pipe Offering
ProceedsFromPipeOffering
21456468
snwv Proceeds From Pipe Offering
ProceedsFromPipeOffering
0
snwv Proceeds From Small Business Administration Ssba Loan
ProceedsFromSmallBusinessAdministrationSSBALoan
614335
snwv Proceeds From Small Business Administration Ssba Loan
ProceedsFromSmallBusinessAdministrationSSBALoan
0
snwv Amortization Of Operating Leases
AmortizationOfOperatingLeases
-14634
snwv Amortization Of Operating Leases
AmortizationOfOperatingLeases
-3396
snwv Increase Decrease In Financing Lease Liabilities
IncreaseDecreaseInFinancingLeaseLiabilities
0
snwv Increase Decrease In Financing Lease Liabilities
IncreaseDecreaseInFinancingLeaseLiabilities
1980
snwv Proceeds From Issuance Of Line Of Credit From Related Party Debt
ProceedsFromIssuanceOfLineOfCreditFromRelatedPartyDebt
90000
snwv Proceeds From Issuance Of Line Of Credit From Related Party Debt
ProceedsFromIssuanceOfLineOfCreditFromRelatedPartyDebt
0
snwv Other Warrant Exercise
OtherWarrantExercise
924649
snwv Other Warrant Exercise
OtherWarrantExercise
0
snwv Accounts Payable And Accrued Employee Compensation Converted To Equity
AccountsPayableAndAccruedEmployeeCompensationConvertedToEquity
0
snwv Accounts Payable And Accrued Employee Compensation Converted To Equity
AccountsPayableAndAccruedEmployeeCompensationConvertedToEquity
36500
snwv Issuance Of Stock For Inducement
IssuanceOfStockForInducement
0
snwv Issuance Of Stock For Inducement
IssuanceOfStockForInducement
44740
snwv Notes Payable Related Parties Accrued Interest Rate In Event Of Default
NotesPayableRelatedPartiesAccruedInterestRateInEventOfDefault
0.1
snwv Percentage Of Rent Adjustment
PercentageOfRentAdjustment
0.03
CY2020Q3 snwv Monthly Rent Payable
MonthlyRentPayable
14651
CY2020Q3 snwv Accrued Executive Severance Current
AccruedExecutiveSeveranceCurrent
167500
CY2019Q4 snwv Accrued Executive Severance Current
AccruedExecutiveSeveranceCurrent
154000
CY2020Q3 snwv Accrued Travel Current
AccruedTravelCurrent
120000
CY2019Q4 snwv Accrued Travel Current
AccruedTravelCurrent
120000
CY2019Q4 snwv Accrued Inventory Current
AccruedInventoryCurrent
167050
CY2020Q3 snwv Accrued Inventory Current
AccruedInventoryCurrent
50275
CY2019Q4 snwv Accrued Outside Services Current
AccruedOutsideServicesCurrent
108033
CY2020Q3 snwv Accrued Outside Services Current
AccruedOutsideServicesCurrent
615547
CY2020Q3 snwv Accrued Clinical Study Expenses Current
AccruedClinicalStudyExpensesCurrent
13650
CY2020Q3 snwv Accrued Board Of Director Fees Current
AccruedBoardOfDirectorFeesCurrent
260000
CY2019Q4 snwv Accrued Board Of Director Fees Current
AccruedBoardOfDirectorFeesCurrent
400000
snwv Class Of Warrant Or Right Expired In Period
ClassOfWarrantOrRightExpiredInPeriod
100000
snwv Class Of Warrant Or Right Exercised In Period
ClassOfWarrantOrRightExercisedInPeriod
8200000
snwv Class Of Warrant Or Right Issued
ClassOfWarrantOrRightIssued
155932645
snwv Residual Value
ResidualValue
13882516
CY2020Q3 snwv Liability Recorded
LiabilityRecorded
7306165
CY2020Q3 snwv License Agreement Initial Term
LicenseAgreementInitialTerm
P5Y
CY2020Q3 snwv License Renwal Period
LicenseRenwalPeriod
P1Y
CY2020Q3 snwv License Agreement Written Notice Required Prior To Expiration Of Current Term
LicenseAgreementWrittenNoticeRequiredPriorToExpirationOfCurrentTerm
P180D
snwv Partnership Fees And Expenses
PartnershipFeesAndExpenses
600000
CY2020Q3 snwv Warrants Issued To Investors And Underwriter
WarrantsIssuedToInvestorsAndUnderwriter
132816250
snwv Loss Gain On Change In Fair Value Of Warrant Liability
LossGainOnChangeInFairValueOfWarrantLiability
-1036101
CY2019Q3 snwv Loss Gain On Change In Fair Value Of Warrant Liability
LossGainOnChangeInFairValueOfWarrantLiability
0
CY2020Q3 snwv Loss Gain On Change In Fair Value Of Warrant Liability
LossGainOnChangeInFairValueOfWarrantLiability
-1036101
snwv Loss Gain On Change In Fair Value Of Warrant Liability
LossGainOnChangeInFairValueOfWarrantLiability
0
CY2020Q3 snwv Warrant Liability Warrants Outstanding
WarrantLiabilityWarrantsOutstanding
67210902
CY2020Q3 snwv Warrant Liability Warrants Outstanding
WarrantLiabilityWarrantsOutstanding
67210902
CY2020Q3 snwv Warrant Liability Fair Value Per Share
WarrantLiabilityFairValuePerShare
0.139
CY2020Q3 snwv Warrant Liability Fair Value Per Share
WarrantLiabilityFairValuePerShare
0.154
CY2020Q3 snwv Warrant Liability Fair Value
WarrantLiabilityFairValue
9320304000
CY2020Q3 snwv Warrant Liability Fair Value
WarrantLiabilityFairValue
10356405000
CY2019Q4 snwv Warrant Liability Current
WarrantLiabilityCurrent
0
CY2020Q3 snwv Warrant Liability Current
WarrantLiabilityCurrent
6440249

Files In Submission

Name View Source Status
0001140361-20-026351-index-headers.html Edgar Link pending
0001140361-20-026351-index.html Edgar Link pending
0001140361-20-026351.txt Edgar Link pending
0001140361-20-026351-xbrl.zip Edgar Link pending
brhc10016968_10q.htm Edgar Link pending
brhc10016968_ex31-1.htm Edgar Link pending
brhc10016968_ex31-2.htm Edgar Link pending
brhc10016968_ex32-1.htm Edgar Link pending
brhc10016968_ex32-2.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R57.htm Edgar Link pending
R58.htm Edgar Link pending
R59.htm Edgar Link pending
R6.htm Edgar Link pending
R60.htm Edgar Link pending
R61.htm Edgar Link pending
R62.htm Edgar Link pending
R63.htm Edgar Link pending
R64.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
snwv-20200930.xml Edgar Link completed
snwv-20200930.xsd Edgar Link pending
snwv-20200930_cal.xml Edgar Link unprocessable
snwv-20200930_def.xml Edgar Link unprocessable
snwv-20200930_lab.xml Edgar Link unprocessable
snwv-20200930_pre.xml Edgar Link unprocessable